Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLOTILLA open-label continuation study of encorafenib + binimetinib (± cetuximab)
jRCT2041220160Not yet recruiting
- Sponsor
- Pfizer
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Open-label, single-arm trial of encorafenib, binimetinib and cetuximab in melanoma, sponsored by Pfizer. Primary endpoints: AEs leading to permanent discontinuation of study intervention and All SAEs. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
encorafenibbinimetinibcetuximab
03
Conditions
melanoma
Beyond the preview
Go deeper on jRCT2041220160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220160.